BioCity's ETA antagonist reduces proteinuria in phase 2 trial of diabetic kidney disease
BioCity Biopharma’s selective endothelin receptor type A antagonist has reduced excess proteins in the urine of patients with diabetic kidney disease, hitting a primary endpoint of a phase 2 trial.
BioCity Biopharma’s selective endothelin receptor type A antagonist has reduced excess proteins in the urine of patients with diabetic kidney disease, hitting a primary endpoint of a phase 2 trial.
